Harrow Health to Attend 31st Annual ROTH Conference on March 18, 2019
March 04 2019 - 7:00AM
Harrow Health, Inc. (NASDAQ: HROW) today announced that it
will be attending the 31st Annual ROTH Conference March 18-19, 2019
at The Ritz Carlton, Laguna Niguel in Dana Point, CA. Mark L.
Baum, the company’s Chief Executive Officer, and Andrew R. Boll,
its Chief Financial Officer, will be hosting one-on-one meetings at
the conference and attendees can contact their Roth Capital
Partners representative to arrange a meeting.
About Harrow Health
Harrow Health, Inc. (NASDAQ: HROW) owns a
portfolio of healthcare businesses, including the nation’s leading
ophthalmology pharmaceutical compounding business,
ImprimisRx. The company holds large equity positions in Eton
Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals,
Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies
founded as subsidiaries of Harrow Health. The Company also
owns royalty rights in certain 505(b)(2) drug candidates being
developed by Eton, Surface, Melt, Mayfield and Radley. Harrow
intends to create, invest in and grow paradigm shifting health care
businesses that put patients first. For more information
about Harrow Health, please visit the Investor Relations section of
the corporate website by clicking here.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995. Any statements in this release that
are not historical facts may be considered such "forward-looking
statements." Forward-looking statements are based on management's
current expectations and are subject to risks and uncertainties
which may cause results to differ materially and adversely from the
statements contained herein. Some of the potential risks and
uncertainties that could cause actual results to differ from those
predicted include our ability to make commercially available our
compounded formulations and technologies in a timely manner or at
all; physician interest in prescribing our formulations; risks
related to our compounding pharmacy operations; our ability to
enter into other strategic alliances, including arrangements with
pharmacies, physicians and healthcare organizations for the
development and distribution of our formulations; our ability to
obtain intellectual property protection for our assets; our ability
to accurately estimate our expenses and cash burn, and raise
additional funds when necessary; risks related to research and
development activities; the projected size of the potential market
for our technologies and formulations; unexpected new data, safety
and technical issues; regulatory and market developments impacting
compounding pharmacies, outsourcing facilities and the
pharmaceutical industry; competition; and market conditions. These
and additional risks and uncertainties are more fully described in
Harrow Health’s filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Such documents may be read free of
charge on the SEC's web site at www.sec.gov. Undue reliance should
not be placed on forward-looking statements, which speak only as of
the date they are made. Except as required by law, Harrow Health
undertakes no obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
Investor Contact:Jon
Pattonjpatton@harrowinc.com858-704-4587
Source: Harrow Health, Inc.
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From May 2024 to Jun 2024
Imprimis Pharmaceuticals, Inc. (delisted) (NASDAQ:IMMY)
Historical Stock Chart
From Jun 2023 to Jun 2024